| Literature DB >> 33194200 |
Yoram Y Fleissig1, Jason E Beare2, Amanda J LeBlanc2, Christina L Kaufman3.
Abstract
As clinical experience with surgical techniques and immunosuppression in vascularized composite allotransplantation recipients has accumulated, vascularized composite allotransplantation for hand and face have become standard of care in some countries for select patients who have experienced catastrophic tissue loss. Experience to date suggests that clinical vascularized composite allotransplantation grafts undergo the same processes of allograft rejection as solid organ grafts. Nonetheless, there are some distinct differences, especially with respect to the immunologic influence of the skin and how the graft is affected by environmental and traumatic insults. Understanding the mechanisms around these similarities and differences has the potential to not only improve vascularized composite allotransplantation outcomes but also outcomes for all types of transplants and to contribute to our understanding of how complex systems of immunity and function work together. A distinct disadvantage in the study of upper extremity vascularized composite allotransplantation recipients is the low number of clinical transplants performed each year. As upper extremity transplantation is a quality of life rather than a lifesaving transplant, these numbers are not likely to increase significantly until the risks of systemic immunosuppression can be reduced. As such, experimental models of vascularized composite allotransplantation are essential to test hypotheses regarding unique characteristics of graft rejection and acceptance of vascularized composite allotransplantation allografts. Rat hind limb vascularized composite allotransplantation models have been widely used to address these questions and provide essential proof-of-concept findings which can then be extended to other experimental models, including mice and large animal models, as new concepts are translated to the clinic. Here, we review the large body of rat hind limb vascularized composite allotransplantation models in the literature, with a focus on the various surgical models that have been developed, contrasting the characteristics of the specific model and how they have been applied. We hope that this review will assist other researchers in choosing the most appropriate rat hind limb transplantation model for their scientific interests.Entities:
Keywords: Hind limb; functional outcomes; heterotopic; orthotopic; rat model; rejection; vascularized composite allotransplantation
Year: 2020 PMID: 33194200 PMCID: PMC7607771 DOI: 10.1177/2050312120968721
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Immunosuppressive regimens following hind limb VCA.[a]
| Immunosuppressant | Dose | Frequency of administration | Time to rejection | References |
|---|---|---|---|---|
| Cyclosporin A (CsA) | 25 mg/kg | Daily for 20 days | Approximately 100 days | Black et al.[ |
| 2 mg/kg | Daily for 20 days | Approximately 20 days | Hewitt et al.[ | |
| 4 mg/kg | Daily for 20 days | Approximately 30 days | Hewitt et al.[ | |
| 8 mg/kg | Daily for 20 days | Approximately 35 days | Hewitt et al.[ | |
| 25 mg/kg | Daily for 20 days | Approximately 60 days | Hewitt et al.[ | |
| 10 mg/kg | Daily for 14 days | 32.9 ± 3.0 days | Kim et al.[ | |
| 10 mg/kg | Daily for 60 days | 67.7 ± 1.9 days | Kim et al.[ | |
| 10 mg/kg | Daily for 20 days, then twice weekly | Mild rejection in 4 of 6 animals at POD116-140 | Benhaim et al.[ | |
| 25 mg/kg | Daily for 20 days, then twice weekly | 61.6 ± 48.24 days | Jones et al.[ | |
| 16 mg/kg | Daily for 10 days | 57 ± 21 days | Ramirez et al.[ | |
| Azathioprine | 10 mg/kg | Daily until rejection | 7.2 ± 0.4 days | Kim et al.[ |
| 5 mg/kg ↓ 2.5 mg/kg (stepdown at Day 7) | Daily for 14 days, stepdown from 5 mg/kg to 2.5 mg/kg at Day 7 | 10 ± 6.2 days | Doi[ | |
| Prednisolone | 10 mg/kg | Daily until rejection | 7.8 ± 1.9 days | Kim et al.[ |
| 5 mg/kg ↓ 2.5 mg/kg (stepdown at Day 7) | Daily for 14 days, stepdown from 5 mg/kg to 2.5 mg/kg at Day 7 | 6.5 ± 0.7 days | Doi[ | |
| Azathioprine + Prednisolone | 5 mg/kg ↓ 2.5 mg/kg 5 mg/kg ↓ 2.5 mg/kg (stepdown at Day 7) | Daily for 14 days, stepdown from 5 mg/kg to 2.5 mg/kg at Day 7 | 15.3 ± 6.1 days | Doi[ |
| Mercaptopurine (6-MP) | 5 mg/kg ↓ 2.5 mg/kg (stepdown at Day 7) | Daily for 14 days, stepdown from 5 mg/kg to 2.5 mg/kg at Day 7 | 9.3 ± 3.2 days | Doi[ |
| Mercaptopurine + Prednsiolone | 5 mg/kg ↓ 2.5 mg/kg 5 mg/kg ↓ 2.5 mg/kg (stepdown at Day 7) | Daily for 14 days, stepdown from 5 mg/kg to 2.5 mg/kg at Day 7 | 7.7 ± 3.5 days | Doi[ |
| RS-61443 (mychophenolic acid) | 30 mg/kg | Daily until rejection | Slight rejection in only 1 of 5 animals at POD231-251 | Benhaim et al.[ |
| 30 mg/kg | Daily for 14 days, then twice weekly | 43.6 ± 15.8 days | Jones et al.[ | |
| Tacrolimus (FK506) | 0.2 mg/kg | Daily for 14 days | 14.7 ± 2.5 days | Arai et al.[ |
| 1 mg/kg | Daily for 14 days | 149.5 ± 63.9 days | Arai et al.[ | |
| 5 mg/kg | Daily for 14 days | 101.7 ± 8.5 days | Arai et al.[ | |
| 2 mg/kg | Daily for 14 days, then 2× a week | 296.1 ± 29.8 days | Jones et al.[ | |
| 1 mg/kg | Daily for 365 days | Indefinite | Song et al.[ | |
| Anti-Lympocyte-Serum + Tacrolimus | 0.5 mL ALS + 0.3 mg/kg Tacrolimus | ALS Daily for 3 days, Tacrolimus daily for days 0–50 | 64.60 ± 0.87 days | Hautz et al.[ |
| 0.5 mL ALS + 0.3 mg/kg Tacrolimus + 1 mg/kg anti-IL-1β | ALS Daily for 3 days, Tacrolimus daily for days 0–50, anti-IL-1β weekly for days 35–100 | 86.60 ± 5.33 days |
ALS: anti-lymphocyte serum.
Studies that used immunosuppression to maintain animals for a short time (weeks) before an intervention are not listed.
Rat hind limb transplantation model.
| Reference | Rat strains[ | Transplant type | Functional outcome | Open-/closed bone | Bone component | Nerves | Skin | Goal/result of study |
|---|---|---|---|---|---|---|---|---|
| Harashina and Buncke[ | Long-Evans Hooded rat[ | Autogenic | Not evaluated | Open | Distal 1/2 femur, lower limb and foot | No nerve repair | Skin associated with lower limb and foot | Studied the effect of perfusion of donor graft with heparinized saline, C-3 kidney preservation solution, or no perfusion on 10 graft survival. Surprisingly, the best results were obtained with no graft perfusion. |
| Shapiro and Cerra[ | Wistar (from Carworth Farms colony) | Autogenic | No active movement, but good passive movement of joints at 4 months. Pain response not evaluated | Open | Distal 1/2 femur, lower limb and foot osteotomy | Sciatic and femoral nerve repair | Skin associated with lower limb and foot | Technical feasibility of surgical procedure. 4 months follow-up and approximately 80% success rate. Hypothesized that condition of tissue at 4 months should have allowed for some functional recovery. |
| Doi[ | Wistar → F344 | Allogeneic | Not evaluated, grafts survived less than three weeks | Open | Distal 1/2 femur, lower limb and foot | Sciatic nerve repair | Skin associated with lower limb and foot | First report of MHC mismatched rat limb transplant, reported timeline of rejection in untreated groups and slight prolongation in Aza/MP group |
| Black et al.[ | F1(LEW/BN) → Lewis | Allogeneic | Recipients responded to pain stimulus at day 65-83 days | Open | Distal 1/2 femur, lower limb and foot | Sciatic and femoral nerve repair | Skin associated with lower limb and foot | First to report significantly prolonged rat limb allograft survival under different doses of Cyclosporine A |
| Lipson et al.[ | F344 → F344 | Syngeneic | Evaluated growth of bone, joint ROM, vascularity over one year | Open | Distal 1/3 femur, the entire knee joint, and the leg with all intrinsic muscles, but without the foot | No nerve repair | No donor skin was transplanted | Described evidence of bone growth after transplantation (actually increased compared to contralateral leg), as well as normal functioning joints with 1 year of follow-up |
| Lipson et al.[ | BN → F344 | Allogeneic | Careful evaluation of bone scans, vascularity, and joint ROM up to one month | Open | Distal 1/3 femur, the entire knee joint, and the leg with all intrinsic muscles, but without the foot | No nerve repair | No donor skin was transplanted | Studied techniques for evaluating rejection of vascularized skeletal tissue. Bone healing was delayed, but did occur, and thrombosis of large vessels did not occur until late in the rejection process in the absence of immunosuppression. |
| Kim et al.[ | Buffalo → Lewis | Allogeneic | Not evaluated | Open | Distal 1/2 femur, lower limb and foot | Sciatic and femoral nerve repair | Skin associated with lower limb and foot | Validated the use of CsA in full MHC mismatch and tested other immunosuppressive agents such as azathioprine and prednisolone. |
| Arai et al.[ | ♀ BN → F344 | Allogeneic | Not evaluated, despite some animals surviving >300 days | Open | Distal 1/2 femur, lower limb and foot | Sciatic nerve repair | Donor skin was attached only in the region of the foot | First report of long term survival with FK506. Survival limited by complications, not rejection. Model is unusual for less skin than other orthotopic grafts. |
| Lee et al.[ | Buffalo → Lewis | Allogeneic | Not possible to evaluate | Both | Six models, heterotopic hind leg, with femoral artery, vein and skin attachment, and five individual vascularized tissue models (skin, subcutaneous tissue, Muscle, bone and blood vessels) all through recipient femoral vessels. | No nerve repair | Full skin on hind limb, vascularized skin pedicle and non-vascularized skin | Short term immune response with and without CsA compared between whole hind limb and individual tissues. The whole limb transplant showed less rejection than individual tissues. Six models, heterotopic hind leg, compared to individual vascularized tissue models (skin, subcutaneous tissue, Muscle, bone and blood vessels) as well as non-vascularized skin and bone grafts. |
| Benhaim et al.[ | BN → F344 | Allogeneic | All animals that survived to 50–60 days regained protective sensation and partial functional return with toe spreading and ambulatory weight bearing | Open | Distal 1/2 femur, lower limb and foot | Sciatic nerve repair | Skin associated with lower limb and foot | Compared graft survival using CsA vs. MMF. Animals were followed for 32 weeks, and while graft survival was similar, MMF groups had much less acute rejection than CsA group. First good description of graft function. |
| Yeh et al.[ | Lewis→Lewis | Syngeneic | Performed cutaneous pinch tests, walking track analysis, scored from 0 (normal) to 100 (total loss of function | Open | Distal 1/2 femur, lower limb and foot, fracture immobilization was done using 18G needle pin, and methyl methacrylate glue | Saphenous nerves not connected (skin area served by them used as control). Repair of tibial, peroneal and sural nerves was performed | Skin associated with lower limb and foot | Goal of study was to prepare a functional walking model of limb transplantation. Cutaneous sensory nerve recovery occurred in 6/6 animals with repaired nerves and walking track analysis showed a function index range from 13.7 to 43.1 (Sciatic); 0.03 to 42.3 (Tibial); and 14.5 to 68.5 (Peroneal) at 60 days post tx. |
| Jones et al.[ | ACI → Lewis | Allogeneic | Not evaluated, although many in FK506 group survived > 300 days | Open | Distal 1/2 femur, lower limb and foot | Sciatic nerve repair | Skin associated with lower limb and foot | Direct comparison of CsA, MMf and FK506 (tacrolimus) with long term intermittent dosing in stronger MHC mismatch. CsA and MMF groups only survived avg of 61 and 43 days, compared to 296 days for tacrolimus |
| Liao et al.[ | Lewis→Lewis | Syngeneic | Not possible to evaluate | Closed | Hind limb fibula and tibia, disarticulated from knee joint and ankle joint | No nerve repair | Partial skin of the crus | Heterotopic model designed to address immunologic vs functional studies. This model also significantly decreased mass of the graft by including only the disarticulated tibia and fibula rather than the entire leg, and by using only partial muscle of the crus and its associated skin |
| Foster et al.[ | ACI→ WF | Allogeneic | Gross motor and sensory re-innervation (weight bearing, toe spread) developed after 60 days in 14/21 animals | Open | Distal 1/2 femur, lower limb and foot | Sciatic and femoral nerve repair | Skin associated with lower limb and foot | Tolerance induction protocol based on sub-lethal conditioning and donor BMT 12 months prior to limb transplant. Mixed chimerism resulted in first report of rejection-free graft survival across a major MHC mismatch without long term immunosuppression |
| Nazzal et al.[ | Lewis→ F344 | Allogeneic | Not possible to evaluate | Open | Distal femur (approximately 5 mm above the knee joint), lower limb | No nerve repair | 2 cm x 2 cm skin island | Development of heterotopic model focused on less time and less morbidity for studies where function is not of interest. Comparison of grafts with and without skin demonstrated grafts with skin rejected faster (12.8 days) than grafts without skin (20.6 days) in the absence of immunosuppression. |
| Ulusal et al.[ | BN→ Lewis | Allogeneic | Not possible to evaluate in either group as animals only followed for two weeks. | Closed | Whole hind limb disarticulated from hip joint | Nerve repair on orthotopic model only | Epigastric skin flap or full donor skin on graft | Direct comparison of surgical times and morbidity of heterotopic vs. orthotopic model. Noted importance of shorter donor femur to prevent vessel torsion. Size of heterotopic graft may still result in altered gait for recipient animal. However, graft size is very similar to orthotopic model if graft mass is a consideration. Closed bone may be beneficial for tolerance studies |
| Song et al.[ | DA→ Lewis | Allogeneic | Performed cutaneous pinch tests, walking track analysis, scored from 0 (normal) to 100 (total loss of function) or Toe Spread Index (TSI) or Print Length Factor (PLF) if walking impaired due to poor sciatic function. EMG of gastrocnemius muscle | Open | Distal 1/2 femur, lower limb and foot | Sciatic nerve repair | Skin associated with lower limb and foot | This study focused on functional recovery comparing allogeneic to syngeneic transplants. Sensory recovery was the same in both groups, evident 30 days post tx, and peaking at most at 68% of normal at one year. Walking analysis also showed similar increases in both groups between 1 and 6 months and plateaued thereafter. Latency in both groups recovered in both groups to about 43%, and amplitude increased through month 9 and was 41% of normal at one year. |
| Ozmen et al.[ | BN→ Lewis | Allogeneic | Not possible to evaluate | Closed | Vascularized disarticulated femur with epigastric skin island | No nerve repair | 4 cm × 5 cm vascularized epigastric skin island with or without vascularized femur | This model has no muscle, nervous or connective tissue, only vascularized skin and a vascularized closed bone. It was developed specifically to address bone marrow-based tolerance studies. |
| Endo et al.[ | Lewis → Lewis | Syngeneic | Compared gait function with and without training using a treadmill. Trained animals walked with more normal plantar surface contact | Open | Mid-thigh level amputation | Sciatic nerve repair | Skin associated with lower limb and foot | The study showed training allowed recovery of more normal plantar foot placement vs. “drop foot” use of the dorsal surface of the foot for ambulation. Studies in an allogeneic model were not performed. |
| Adamson et al.[ | ACI→WF | Allogeneic | Not possible to evaluate | Open | Distal femur, tibia cut to level of fibular bifurcation | No nerve repair | 3 cm × 2 cm skin island | Heterotopic model developed to study tolerance to VCA. Less bone and muscle transplanted than most other models. Bone marrow cavity flushed to reduce the number of bone marrow progenitors transplanted with the donor graft. Unlike other heterotopic models, the flap is inset posteriorly in the gluteal region of the recipient leg to promote normal ambulation. |
| Chang et al.[ | BN → WF | Allogeneic | Not possible to evaluate | Open | 2/3 of femur from thinnest section of distal femur to proximal femur neck | No nerve repair | Epigastric skin flap | Slightly smaller flap, with open femur bone only. Inserted on inguinal side of recipient leg. Shorter operative and ischemic times compared to other reported models. |
| Zhang et al.[ | Wistar→ SD | Allogeneic | Not possible to evaluate | Open | Distal femur, lower limb and foot | No nerve repair | Skin associated with lower limb and foot | Similar decrease in surgical time and increase in success rate compared to |
| Sacks et al.[ | WF → Lewis | Allogeneic | Was not evaluated | Open | Mid-femur osteotomy of donor graft | Sciatic nerve repair | Skin associated with lower limb and foot | Presented a dual surgeon approach that allows two orthotopic transplants to be completed simultaneously and compared with operative times and morbidity of a single surgeon approach. Demonstrated shorter operative time than single surgeon procedures, and similar morbidity rates to heterotopic limb transplants. |
| Tsuji et al.[ | GFP-Tg Lewis → Lewis | Transgenic to Syngeneic | Looked at distal motor latencies of sciatic nerve, and histology of regenerating axons, but no functional tests such as sensation or gait analysis. | Open | Mid-thigh level amputation | Sciatic nerve repair | Skin associated with lower limb and foot | Fluorescent-labeled transgenic model which allowed the visualization of donor sciatic nerve regenerating beyond the nerve anastomosis, and the negative effect of ischemia on this regeneration, as well as muscle atrophy. |
| Ramirez et al.[ | BN→ Lewis | Allogeneic | Not possible to evaluate | Open | Distal femur, tibia cut to level of fibular bifurcation | No nerve repair | 3 cm × 3 cm skin island + full-thickness hemi-abdominal wall | Combined a heterotopic OMC flap with a separate abdominal wall flap. Concluded that increased graft mass negatively affected tolerance induction, but tolerance was not achieved in the majority of animals in any group. |
| Arav et al.[ | Lewis → Lewis | Syngeneic | Not possible to evaluate | Open | Mid-thigh level amputation | No nerve repair | Skin associated with lower limb and foot | First group to report cryopreserved and thawed donor heterotopic OMC flaps in a syngeneic model. Grafts were successful and viable for the three days of the study. |
| Fleissig et al.[ | BN→Lewis | Allogeneic | Not possible to evaluate | Closed | Hind limb fibula and tibia, disarticulated from knee joint and ankle joint | No nerve repair | 3.5 cm × 2 cm skin island | Modified surgical model, focus on closed fibula and tibula for use in immunological studies. Results in less stress and pain, decreased flap mass and lower graft profile. |
| Messner et al.[ | BN→Lewis | Allogeneic | Orthotopic model with standardized mechanical irritation of transplanted foot with sonic toothbrush | Open | Mid-femur osteotomy of donor graft | Sciatic nerve repair | Skin associated with lower limb and foot | Paired orthotopic model with repetitive 10 minute mechanical irritation of planta pedis of transplanted hind limb. Model compared not only allo to syngeneic transplants, but also syngeneic transplants under tacrolimus immunosuppression. Confirmed that mechanical irritation resulted in increased rejection, and healing was delayed compared to syngeneic controls. |
ACI: ACI rat; WF: Wistar Furth rat—inbred rat strain based on Wistar rat; Wistar: outbred rat strain; SD: Sprague–Dawley rat; CsA: Cyclosporin A; BN: Brown Norway rat; DA: Dark Agouti rat; Lewis: Lewis rat; GFP-Tg: green fluorescent protein transgenic rat; MMF: mychophenolate mofetil; VCA: vascularized composite allograft; OMC: osteomyocutaneous; F344: Fischer 344 rat.
Extensive summary of the rat hind limb VCA models utilized throughout the years. Note that this table focuses on changes to the surgical procedure and design of the rat hind limb model, as well as outcomes and advancements in the field. It does not include all of the very important rat hind limb transplantation studies which used surgical models combined with different tolerance induction protocols or biological or pharmaceutical interventions that investigated mechanisms of graft rejection, as these have been discussed elsewhere in this review.
Most studies using an allogeneic model also performed syngeneic models as a control.
Harashina and Buncke did not designate strain, but photos show a hooded rat, likely the outbred Long–Evans strain.